Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03526848 · ClinicalTrials.gov registry record · Phase 1
3BNC117 and 10-1074 in ART-treated Individuals
A Phase 1 study, sponsored by Rockefeller University.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT03526848 is a Phase 1 study that has completed, run by Rockefeller University. The registered enrollment target is 26 participants.
The verdict
NCT03526848, a Phase 1 study, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The proposed study is a phase 1, open label, randomized study to evaluate the safety and antiretroviral activity of seven infusions of 3BNC117 and 10-1074, administered intravenously at 30 mg/kg dose level, in human immunodeficiency virus (HIV)-infected individuals on combination antiretroviral therapy (ART) and during an analytical interruption of ART.
Interventions
- DRUG 3BNC117
- DRUG 10-1074
- OTHER Analytical treatment interruption
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2018-06-05 |
| Est. Completion | 2022-02-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03526848
The ClinicalTrials.gov registry entry for NCT03526848 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 3BNC117 is the first listed.
NCT03526848 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03526848 about?
NCT03526848 is a clinical study titled "3BNC117 and 10-1074 in ART-treated Individuals". The proposed study is a phase 1, open label, randomized study to evaluate the safety and antiretroviral activity of seven infusions of 3BNC117 and 10-1074, administered intravenously at 30 mg/kg dose level, in human immunodeficiency virus (HIV)-infected individuals on combination antiretroviral ther...
What is the current status of trial NCT03526848?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2018-06-05. Estimated completion is 2022-02-11.
What interventions are being tested in trial NCT03526848?
The interventions under investigation include: 3BNC117 (DRUG), 10-1074 (DRUG), Analytical treatment interruption (OTHER).
Who is sponsoring clinical trial NCT03526848?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.